

Publications Stefan Eichmüller

Total number of publications: 112, including 93 original papers and 16 peer reviewed reviews and letters. Cumulative Impact Factors: 717. Accordingly to publons calculation sum of the times cited 5,610; H-index: 36. Google Scholar: 8,829 citations; H-index: 47.

An actual listing can be found via this [link to Pubmed](#). Details on publications see my profile on [Web of Science](#).

Original articles (asterisks delineate shared author position)

- 1) Meyer M, Parpoulas C, Barthélémy T, Becker JP, Charoentong P, Lyu Y, Börsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, Schmidt P, Pipkorn R, **Eichmüller SB**, Steinberger P, Lindner K, Poschke IC, Platten M, Fröhling S, Riemer AB, Hassel J, Roberti MP, Jäger D, Zörnig I, and Momburg F (accepted) MediMer: A versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection. *Frontiers in Immunology* 14: 1294565.
- 2) Kordaß T, Chao T-Y, Osen W, and **Eichmüller SB** (2023) Novel microRNAs modulating ecto-5'-nucleotidase expression. *Frontiers in Immunology* 14.
- 3) Pane AA, Kordaß T, Hotz-Wagenblatt A, Dickes E, Kopp-Schneider A, Will R, Seliger B, Osen W, and **Eichmüller SB** (2023) miRNAs affecting the susceptibility of melanoma cells to CD8+ T cell-mediated cytolysis. *Clin Transl Med* 13(2): e1186.
- 4) Chao T-Y*, Kordaß T*, Osen W, and **Eichmüller SB** (2023) SOX9 is a target of miR-134-3p and miR-224-3p in breast cancer cell lines. *Mol Cell Biochem* 478(2):305-315.
- 5) Hartmann L, Osen W, Eichmüller OL, Kordaß T, Furkel J, Dickes E, Reid C, Debus J, Brons S, Abdollahi A, Moustafa M, Rieken S, and **Eichmüller SB** (2022) Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. *Cancer Lett.* 550.
- 6) Kehl N, Kilian M, Michel J, Wagner TR, Uhrig S, Brobeil A, Sester LS, Blobner S, Steiger S, Hundemer M, Weinhold N, Rippe K, Fröhling S, **Eichmüller SB**, Bunse L, Müller-Tidow C, Goldschmidt H, Platten M, Raab MS, and Friedrich M (2022) IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. *Journal for ImmunoTherapy for Cancer* 10.
- 7) Hernández-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, Landua SL, Salm EVd, Trautmann CL, Raffel S, Grünschläger F, Lutz R, Ghosh M, Renders S, Correia N, Donato E, Dixon KO, Hirche C, Andresen C, Robens C, Werner PS, Boch T, Eisel D, Osen W, Pilz F, Przybylla A, Klein C, Buchholz F, Milsom MD, Essers MAG, **Eichmüller SB**, Hofmann W-K, Nowak D, Hübschmann D, Hundemer M, Thiede C, Bullinger L, Müller-Tidow C, Armstrong SA, Trumpp A, Kuchroo VK, and Haas S (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell Stem Cell* 29(5):760-75.
- 8) Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimsky G, **Eichmüller SB**, Deimling Av, Wick W, Sahm F, Platten M, and Bunse L (2022) T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas. *Clin Cancer Res* 28:378-389.
- 9) Hartmann L, Schröter P, Osen W, Baumann D, Offringa R, Moustafa M, Will R, Debus J, Brons S, Rieken S, and **Eichmüller SB** (2020) Photon versus carbon ion irradiation – immunomodulatory effects exerted on various murine tumor cell lines. *Scientific Reports* 10: 21517.
- 10) Ran T, **Eichmüller SB***, Schmidt P, and Schlander M* (2020) Cost of decentralized CAR T cell production in an academic non-profit setting. *Int J Cancer* 147: 3438-3445.
- 11) Busch E, Kubon KD, Mayer JKM, Pidelaserra-Martí G, Albert J, Hoyler B, Heidbuechel JPW, Stephenson KB, Lichty BD, Osen W, **Eichmüller SB**, Jäger D, Ungerechts G, and

- Engeland CE (2020) Measles vaccines designed for enhanced CD8+ T cell activation. *Viruses* 12:242.
- 12) Hörhold F*, Eisel D*, Oswald M, Kolte A, Röhl D, Osen W, **Eichmüller SB**, and König R (2020) Reprogramming of macrophages employing gene regulatory and metabolic network models. *PLOS Computational Biology* 16: e1007657.
 - 13) Schröter P, Hartmann L, Osen W, Baumann D, Offringa R, Eisel D, Debus J, **Eichmüller SB***, and Rieken S* (2020) Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line. *Scientific Reports* 10:686.
 - 14) Das K, Eisel D, Vormehr M, Müller-Decker K, Hommertgen A, Jäger D, Zörnig I, Feuerer M, Kopp-Schneider A, Osen W, and **Eichmüller SB** (2019) A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice. *BMC Cancer* 19:914.
 - 15) Gangkofner DS, Holzinger D, Schröder L, **Eichmüller SB**, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende C, Dyckhoff G, Boscolo-Rizzo P, Ezic J, Marienfeld RB, Möller P, Völkel G, Kraus J, Kestler H, Brunner C, Schuler PJ, Wigand M, Theodoraki MN, Döscher J, Hoffmann TK, Pawlita M, Waterboer T, and Laban S (2019) Patterns of antibody responses to non-viral cancer antigens in head and neck squamous cell carcinoma patients differ by Human papillomavirus status. *Int J Cancer* 145: 3436-3444.
 - 16) Laban S, Gangkofner DS, Holzinger D, Schroeder L, **Eichmüller SB**, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende C, Dyckhoff G, Boscolo-Rizzo P, Ezic RB, Marienfeld RB, Möller P, Völkel G, Kraus J, Kestler H, Brunner C, Schuler PJ, Wigand M, Theodoraki MN, Döscher J, Hoffmann TK, Pawlita M, Waterboer T, and Butt J (accepted) Antibody responses to cancer antigens identify patients with a poor prognosis among HPV-positive and HPV-negative head and neck squamous cell carcinoma patients. *Clin Cancer Res* 25: 7405-7412.
 - 17) Eisel D, Das K, Dickes E, König R, Osen W, and **Eichmüller SB** (2019) Cognate interaction with CD4+ T cells instructs tumor-associated macrophages to acquire M1-like phenotype. *Front Immunol* 10(219).
 - 18) Sharbi-Yunger A, Grees M, Gal C, Bassan D, **Eichmüller SB**, Tzehoval E, Utikal J, Umansky V, and Eisenbach L (2019) A universal anti-cancer vaccine: chimeric invariant chain potentiates the inhibition of melanoma progression and improvement of survival. *Int J Cancer* 144: 909-921.
 - 19) Ast V*, Kordaß T*, Oswald M, Kolte A, Eisel D, Osen W, **Eichmüller SB**, Berndt A, and König R (2018) Piecewise linear regression identifies miR-192, miR-200c and miR-17 as fibroblast-mediated inhibitors of colorectal cancer invasion. *Oncotarget* 9(85): 35559-35580.
 - 20) Kordaß T, Weber CEM, Eisel D, Pane AA, Osen W, and **Eichmüller SB** (2018) miR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion. *Oncotarget* 9(65): 32507-32522.
 - 21) Grees M, Sharbi-Yunger A, Evangelou C, Baumann D, Cafri G, Tzehoval E, **Eichmüller SB**, Offringa R, Utikal J, Eisenbach L, and Umansky V (2018) Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. *Oncolmmunology* 7: e1445457.
 - 22) Michels J, Becker N, Suci S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi S, Halama N, Pawlita M, Waterboer T, **Eichmüller SB**, Jäger D, Eggermont AMM, and Zörnig I (2018) Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC 18961 trial. *Oncolmmunology* 7: e1428157.

- 23) Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, **Eichmüller SB**, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, and Schüssler-Lenz M (2018) Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies - the German Cancer Consortium approach. *Cancer Immunol Immunol* 67(4):513-523.
- 24) Lv N, Hao S, Luo C, Abukiwan A, Hao Y, Gai F, Huang W, Huang L, Xiao X, **Eichmüller SB**, and He D (2018) miR-137 inhibits melanoma cell proliferation through downregulation of GLO1. *Sci China Life Sci* 61: 541-549.
- 25) Das K*, Eisel D*, Lenkl C, Goyal A, Diederichs S, Dickes E, Osen W, and **Eichmüller SB** (2017) Generation of murine β 2-microglobulin deficient tumor cell lines using the CRISPR/Cas9 system. *PLoS ONE* 12: e0174077.
- 26) Weber CEM, Luo C, Hotz-Wagenblatt A, Gardyan A, Kordaß T, Holland-Letz T, Osen W, and **Eichmüller SB** (2016) miR-339-3p is a tumor suppressor in melanoma. *Cancer Res* 76: 3562-71.
- 27) Werner S, Chen H, Butt J, Michel A, Knebel P, Holleczeck B, Zörnig I, **Eichmüller SB**, Jäger D, Pawlita M, Waterboer T, and Brenner H (2016) Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. *Scientific Reports* 6:25467.
- 28) Kordaß T, Weber CEM, Oswald M, Ast V, Bernhardt M, Novak D, Utikal J, **Eichmüller SB***, and König R* (2016) SOX5 is involved in balanced MITF regulation in human melanoma cells. *BMC Med Genomics* 9:10.
- 29) Chen H, Werner S, Butt J, Zörnig I, Knebel P, Michel A, **Eichmüller SB**, Jäger D, Waterboer T, Pawlita M, and Brenner H (2016) Prospective evaluation of novel serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. *Oncotarget* 7:16420-32.
- 30) Lei J, Osen W, Gardyan A, Hotz-Wagenblatt A, Gissmann L, **Eichmüller SB**, and Löchelt M (2015) Replication-competent foamy virus vaccine vectors as novel epitope scaffolds for immunotherapy. *Plos One* 10:e0138458.
- 31) Pfirschke C, Gebhardt C, Zörnig I, Pritsch M, **Eichmüller SB**, Jäger D, Enk A, and Beckhove P (2015) T cell responses in early stage melanoma patients occur frequently and are not associated with humoral response. *Cll* 64:1369-81.
- 32) Hao S, Luo C, Abukiwan A, Wang G, He J, Huang L, Weber CEM, Lv N, Xiao X, **Eichmüller SB***, and He D* (2015) miR-137 inhibits proliferation of melanoma cells by targeting PAK2. *Exp Dermatol.* 24:947-52.
- 33) Gardyan A, Osen W, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, and **Eichmüller SB** (2015) Identification of NY-BR-1-specific CD4+ T cell epitopes using HLA-transgenic mice. *Int J Cancer* 136:2588-97.
- 34) Zörnig I, Halama N, Bermejo JL, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schandendorf D, Falk C, **Eichmüller SB***, and Jäger D* (2015) Spontaneous humoral antibody responses against tumor-associated antigens in malignant melanoma patients. *Int J Cancer*, 136:138-151.
- 35) Amann PM, Czaja K, Bazhin AV, Rühl R, **Eichmüller SB**, Merk HF, and Baron JM (2014) LRAT overexpression diminishes intracellular levels of biologically active retinoids and reduces retinoid anti-tumor efficacy in the murine melanoma B16F10 cell line. *Skin Pharmacol Physiol.* 28: 205-212.
- 36) Amann PM, Czaja K, Bazhin AV, Rühl R, Skazik C, Heise R, Marquardt Y, **Eichmüller SB**, Merk HF, and Baron JM (2014) Knockdown of lecithin retinol acyltransferase (LRAT) increases all-trans retinoic acid levels and restores retinoid sensitivity in malignant melanoma cells. *Experimental Dermatol.* 23: 832-837.

- 37) Schacht T, Oswald M, Eils R, **Eichmüller SB**, and König R (2014) Estimating the activity of transcription factors by the effect on their target genes. *Bioinformatics*, 30:i401-i407.
- 38) Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Grabowska AK, Vogler I, Diekmann J, Trautwein N, **Eichmüller SB**, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, Deimling Av, Wick W, and Platten M (2014) A vaccine targeting mutant IDH1 induces antitumor immunity. *Nature*, 512: 324-327.
- 39) Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D, and **Eichmüller SB** (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. *Cancer Letters* 341: 240-247.
- 40) Hassel JC, Amann PM, Schadendorf D, **Eichmüller SB**, Nagler M, and Bazhin AV (2013) Lecithin/retinol acyltransferase as a potential prognostic marker for malignant melanoma. *Exp Dermatol* 22: 757-759.
- 41) Simon-Keller K, Paschen A, Hombach A, Ströbel P, Coindre JM, **Eichmüller SB**, Vincent A, Gattenlöhner S, Hoppe F, Leuschner I, Stegmaier S, Koscielniak E, Leverkus M, Altieri DC, Abken H, and Marx A (2013) Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholin receptor-redirected T cells. *Am J Pathol* 182: 2121-2131.
- 42) Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schitteck B, Schadendorf D, Diederichs S, and **Eichmüller SB** (2013) miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. *J Invest Dermatol* 133: 768-775.
- 43) Grund SE, Polycarpou-Schwarz M, Luo C, **Eichmüller SB**, and Diederichs S (2012) Rare Drosha splice variants are deficient in microRNA processing but do not affect general microRNA expression in cancer cells. *Neoplasia* 14: 238-248.
- 44) Bai A, Milde T, Remke M, Rolli C, Hielscher T, Cho Y-J, Kool M, Northcott P, Jugold M, Bahzin A, **Eichmüller SB**, Kulozik A, Pscherer A, Benner A, Taylor M, Kemkemer R, Witt O, Korshunov A, Lichter P, and Pfister S (2012) MicroRNA-182 promotes metastatic dissemination of non-sonic hedgehog-medulloblastoma. *Acta Neuropathologica* 123: 529-538.
- 45) Savchenko MS, Goncharskaia MA, Skorikova EE, **Eichmüller SB**, Kushlinsky NE, Bazhin AV, and Philippov PP (2012) Autoantibodies against a Ca²⁺-binding protein recoverin in blood sera of patients with various oncological diseases. *Oncology Letters* 3: 377-382.
- 46) Amann PM, Luo C, Owen RW, Hofmann C, Freudenberger M, Schadendorf D, **Eichmüller SB**, and Bazhin AV (2012) Vitamin A metabolism in benign and malignant skin cells: Importance of lecithin/retinol acyltransferase and RPE65. *J Cell Physiol* 227: 718-728.
- 47) Amann PM, Hofmann C, Freudenberger M, Holland-Cunz S, **Eichmüller SB**, and Bazhin AV (2012) Expression and activity of alcohol and aldehyde dehydrogenases in melanoma cells and in melanocytes. *J Cell Biochem* 113: 792-799.
- 48) Amann PM, Schadendorf D, Owen RW, Korn B, **Eichmüller SB**, Bazhin AV (2011) Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT. *Exp Dermatol*. 20: 373-375.
- 49) Osen W, Soltek S, Song M, Leuchs B, Steitz J, Tüting T, **Eichmüller SB**, Ngyuen XD, Schadendorf D, and Paschen A (2010) Comprehensive screening of human tumor antigens for CD4+ T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. *PLoS ONE* 5: e14137.
- 50) Simon-Keller K, Paschen A, **Eichmüller S**, Gattenlohner S, Barth S, Koscielniak E, Leuschner I, Stobel P, Hombach A, Abken H, and Marx A (2010) [Adoptive T-cell therapy of rhabdomyosarcoma]. *Pathologe* 31 Suppl 2: 215-220.

- 51) Dummer R, **Eichmüller S**, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, Bleuzen P, Bataille V, Derbij A, Wiedemann N, Waterboer T, Luskay M, Acres B and Urosevic-Maiwald M (2010) Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-gamma) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas. *Mol Ther* 18: 1244–1247.
- 52) Lange A, Kistler C, Jutzi T B, Bazhin A V, Schadendorf D, **Eichmüller SB** (2009) Detergent fractionation with subsequent SSH reveals genes coding for plasma membrane associated proteins enriched in cutaneous T cell lymphoma. *Exp Dermatol* 18: 527-35.
- 53) Bazhin AV, Dalke C, Willner N, Abschütz O, Wildberger HG, Philippov PP, Dummer R, Graw J, Hrabé de Angelis M, Schadendorf D, Umansky V and **Eichmüller SB** (2009) Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. *Int J Cancer* 124: 140-149.
- 54) Hartmann TB, Mattern E, Wiedemann N, van Doorn R, Willemze R, Niikura T, Hildenbrand R, Schadendorf D and **Eichmüller SB** (2008) Identification of selectively expressed genes and antigens in CTCL. *Exp Dermatol* 17: 324-334.
- 55) Bazhin AV, Schadendorf D, Owen RW, Zernii EY, Philippov PP and **Eichmüller SB** (2008) Visible light modulates the expression of cancer-retina antigens. *Mol Cancer Res* 6: 110-118.
- 56) Lee M, Kistler C, Hartmann TB, Li F, Dummer R, Dippel E, Booken N, Klemke CD, Schadendorf D and **Eichmüller SB** (2007) Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins. *Cancer Immunol Immunother* 56: 783-795.
- 57) Bazhin AV, Wiedemann N, Schnölzer M, Schadendorf D and **Eichmüller SB** (2007) Expression of GAGE family proteins in malignant melanoma. *Cancer Lett* 251: 258–267.
- 58) Bazhin AV, Schadendorf D, Willner N, De Smet C, Heinzelmann A, Tikhomirova NK, Umansky V, Philippov PP and **Eichmüller SB** (2007) Photoreceptor proteins as cancer-retina antigens. *Int J Cancer* 120: 1268-1276.
- 59) Zeng J, Müller-Berghaus J, Nguyen XD, Klüter H, Schönhaber H, Song M, Schwinn N, Schadendorf D, Goerdts S, **Eichmüller S*** and Dippel E* (2006) Identification of HLA class I dependent immunogenic peptides from clonotypic TCR expressed in cutaneous T cell lymphoma. *Int J Cancer* 119: 2476-2480.
- 60) Devitt G, Meyer C, Wiedemann N, **Eichmüller S**, Kopp-Schneider A, Haferkamp A, Hautmann R and Zöller M (2006) Serological analysis of human renal cell carcinoma. *Int J Cancer* 118: 2210-2219.
- 61) Hartmann TB, Bazhin AV, Schadendorf D and **Eichmüller SB** (2005) SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. *Int J Cancer* 114: 88-93.
- 62) Hartmann TB, Thiel D, Dummer R, Schadendorf D and **Eichmüller S** (2004) SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. *Br J Dermatol* 150: 252-258.
- 63) Gerhardt A, Usener D, Keese M, Sturm J, Schadendorf D and **Eichmüller S** (2004) Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. *Cancer Letters* 208: 197-206.
- 64) Fellenberg F, Hartmann TB, Dummer R, Usener D, Schadendorf D and **Eichmüller S** (2004) GBP-5 splicing variants: new guanylate-binding proteins with tumor-associated expression and antigenicity. *J Invest Dermatol* 122: 1510-1570.

- 65) Ehlken H, Schadendorf D and **Eichmüller S** (2004) Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. *Int J Cancer* 108: 307-313.
- 66) Dummer R, Hassel JC, Maier T, Slos P, Fellenberg F, **Eichmüller S**, Acres B, Bataille V, Squiban P, Burg G and Urosevic M (2004) Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. *Blood* 104: 1631-1638.
- 67) Usener D, Schadendorf D, Koch J, Dübel S and **Eichmüller S** (2003) cTAGE: a cutaneous T-cell lymphoma associated antigen family with tumor-specific splicing. *J Invest Dermatol* 121: 198-206.
- 68) Usener D, Gerhardt A, Schadendorf D and **Eichmüller S** (2003) Sero-reactivity against MAGE-A and LAGE-1 proteins in melanoma patients. *Br J Dermatol* 149: 282-288.
- 69) **Eichmüller S**, Usener D, Thiel D and Schadendorf D (2003) Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. *Int J Cancer* 104: 482-487.
- 70) Götte K, Usener D, Riedel F, Hörmann K, Schadendorf D and **Eichmüller S** (2002) Tumor associated antigens as possible targets for immune therapy in head and neck cancer: Comparative mRNA expression analysis of RAGE and GAGE genes. *Acta Otolaryngol* 122: 546-552.
- 71) **Eichmüller S**, Usener D, Jochim A and Schadendorf D (2002) mRNA expression of tumor-associated antigens in melanoma tissues and cell lines. *Exp Dermatol* 11: 292-301.
- 72) **Eichmüller S**, Usener D, Dummer R, Stein A, Thiel D and Schadendorf D (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. *Proc Natl Acad Sci U S A* 98: 629-634.
- 73) Paus R, van der Veen C, **Eichmüller S**, Kopp T, Hagen E, Müller-Röver S and Hofmann U (1998) Generation and cyclic remodeling of the hair follicle immune system in mice. *J Invest Dermatol* 111: 7-18.
- 74) **Eichmüller S**, van der Veen C, Moll I, Hermes B, Hofmann U, Müller-Röver S and Paus R (1998) Clusters of Perifollicular Macrophages in Normal Murine Skin: Physiological Degeneration of Selected Hair Follicles by "Programmed Organ Deletion"? *J Histochem Cytochem* 46: 361-370.
- 75) Paus R, Foitzik K, Welker P, Bulfone-Paus S and **Eichmüller S** (1997) Transforming growth factor- β receptor type I and type II expression during murine hair follicle development and cycling. *J Invest Dermatol* 109: 518-526.
- 76) Panteleyev AA, Paus R, Wanner R, Nürnberg W, **Eichmüller S**, Thiel R, Zhang J, Henz BM and Rosenbach T (1997) Keratin 17 gene expression during the murine hair cycle. *J Invest Dermatol* 108: 324-329.
- 77) Furkert J, Klug U, Slominski A, **Eichmüller S**, Mehlis B, Kertscher U and Paus R (1997) Identification and measurement of β -endorphin levels in the skin during induced hair growth in mice. *Biochim Biophys Acta* 1336: 315-322.
- 78) Botchkarev VA, **Eichmüller S**, Peters E, Pietsch P, Johansson O, Maurer M and Paus R (1997) A simple immunofluorescence technique for simultaneous visualization of mast cells and nerve fibers reveals selectivity and hair cycle-dependent changes in mast cell-nerve fiber contacts in murine skin. *Arch Dermatol Res* 289: 292-302.
- 79) Botchkarev VA, **Eichmüller S**, Johansson O and Paus R (1997) Hair cycle-dependent plasticity of skin and hair follicle innervation in normal murine skin. *J Comp Neurol* 386: 379-395.

- 80) **Eichmüller S**, Stevenson PA and Paus R (1996) A new method for double immunolabelling with primary antibodies from identical species. *J Immunol Methods* 190: 255-265.
- 81) **Eichmüller S** and Schäfer S (1995) Sensory neuron development revealed by taurine immunocytochemistry in the honeybee. *J Comp Neurol* 352: 297-307.
- 82) Paus R, Hofmann U, **Eichmüller S** and Czarnetzki BM (1994) Distribution and changing density of gamma-delta T cells in murine skin during the induced hair cycle. *Br J Dermatol* 130: 281-289.
- 83) Paus R, Handjiski B, **Eichmüller S** and Czarnetzki BM (1994) Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. *Am J Pathol* 144: 719-734.
- 84) Paus R, Handjiski B, Czarnetzki BM and **Eichmüller S** (1994) A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A. *J Invest Dermatol* 103: 143-147.
- 85) Paus R, **Eichmüller S**, Hofmann U and Czarnetzki BM (1994) Expression of classical and non-classical MHC class I antigens in murine hair follicles. *Br J Dermatol* 131: 177-183.
- 86) Kreissl S*, **Eichmüller S***, Bicker G, Rapus J and Eckert M (1994) Octopamine-like immunoreactivity in the brain and suboesophageal ganglion of the honeybee. *J Comp Neurol* 348: 583-595.
- 87) Kaatz H-H, **Eichmüller S** and Kreissl S (1994) Stimulatory effect of octopamine on juvenile hormone biosynthesis in honey bees: Physiological and immunocytochemical evidence. *J Insect Physiol* 40: 865-872.
- 88) Menzel R, Durst C, Erber J, **Eichmüller S**, Hammer M, Hildebrandt H, Maelshagen J, Müller U, Rosenboom H, Rybak J, Schäfer S and Scheidler A (1994) The Mushroombodies in the Honeybee: From Molecules to Behavior. *Neural Basis of Behavioral Adaptations Fortschritte der Zoologie* 81-102.
- 89) Handjiski B, **Eichmüller S**, Hofmann U, Czarnetzki BM and Paus R (1994) Alkaline phosphatase activity and localization during the murine hair cycle. *Br J Dermatol* 131: 303-310.
- 90) Durst C, **Eichmüller S** and Menzel R (1994) Development and experience lead to increased volume of subcompartments in the honeybee mushroom body. *Behav Neural Biol* 62: 259-263.
- 91) Rybak J and **Eichmüller S** (1993) Structural plasticity of an immunocytochemically identified set of honeybee olfactory interneurons. *Acta Biologica Hungaria* 44(1): 61-65.
- 92) **Eichmüller S**, Hammer M and Schäfer S (1991) Neurosecretory cells in the honeybee brain and suboesophageal ganglion show FMRFamide-like immunoreactivity. *J Comp Neurol* 312: 164-174.
- 93) Menzel R, Chittka L, **Eichmüller S**, Geiger K, Peitsch D and Knoll P (1990) Dominance of celestial cues over landmarks disproves map-like orientation in honey bees. *Z Naturforsch* 45c: 723-726.

Letters and reviews (peer reviewed)

- 94) Ran T, **Eichmüller SB***, Schmidt P, and Schlander M* (2021) Reply to comments on "Cost of decentralized CAR T cell production in an academic non-profit setting". *Int J Cancer* 148(2):516-517.

- 95) Kordaß T, Osen W, and **Eichmüller SB** (2018) Controlling the immune suppressor: transcription factors and miRNAs regulating CD73/NT5E. *Frontiers in Immunology*, 9(813).
- 96) **Eichmüller SB**, Osen W, Mandelboim O, and Seliger B (2017) Immune modulatory microRNAs involved in tumor attack and tumor immune escape. *J Natl Cancer Inst.* 109(10).
- 97) Luo C, Weber CEM, Osen W, Bosserhoff A-K, **Eichmüller SB** (2014) The role of microRNAs in melanoma. *Eur J Cell Biol*, 93: 11-22.
- 98) Amann PM, **Eichmüller SB**, Schmidt J, Bazhin AV (2011) Regulation of gene expression by retinoids. *Curr Med Chem* 18: 1405-1412.
- 99) Schwartz-Albiez R, Laban S, **Eichmüller S** and Kirschfink M (2008) Cytotoxic natural antibodies against human tumors: an option for anti-cancer immunotherapy? *Autoimmunity Reviews* 7: 491-495.
- 100) **Eichmüller SB** and Bazhin AV (2007) Onconeural versus paraneoplastic antigens? *Curr Med Chem* 14: 2489-2494.
- 101) Bazhin AV, Schadendorf D, Philippov PP and **Eichmüller SB** (2007) Recoverin as a cancer-retina antigen. *Cancer Immunol Immunother* 56: 110-116.
- 102) **Eichmüller S** (2006) Entwicklung von spezifischen Immuntherapien in der Dermato-Onkologie. *Akt Dermatol* 32: 78-85.
- 103) Paschen A, **Eichmüller S** and Schadendorf D (2004) Identification of tumor antigens and T-cell epitopes, and its clinical application. *Cancer Immunol Immunother* 53: 196-203.
- 104) **Eichmüller S** (2002) Towards defining specific antigens for cutaneous lymphomas. *Onkologie* 25: 448-454.
- 105) Müller-Röver S, Handjiski B, van der Veen C, **Eichmüller S**, Foitzik K, McKay I, Stenn K and Paus R (2001) A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. *J Invest Dermatol* 117: 3-15.
- 106) Paus R, Müller-Röver S, van der Veen C, Maurer M, **Eichmüller S**, Ling G, Hofmann U, Foitzik K, Mecklenburg L and Handjiski B (1999) Review article: A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. *J Invest Dermatol* 113: 523-532.
- 107) Paus R, Peters EMJ, **Eichmüller S** and Botchkarev VA (1997) Neural mechanisms of hair growth control. *J Investig Dermatol Symp Proc* 2: 61-68.
- 108) Paus R, Handjiski B, Czarnetzki BM and **Eichmüller S** (1994) Biologie des Haarfollikels. *Hautarzt* 45: 808-825.

Reviews and book chapters (not peer reviewed)

- 109) Schadendorf D, Paschen A and **Eichmüller S** (2004) Immunological strategies to fight cancer. *Skin immune system (SIS): cutaneous immunology and clinical immunodermatology* 745-770.
- 110) **Eichmüller S** and Dippel E (2004) Entwicklung einer Immuntherapie für Lymphome der Haut. *Report Tumorzentrum Heidelberg/Mannheim* 4: 15-18.
- 111) Schadendorf D, Hofmann U and **Eichmüller S** (2001) Klinische und experimentelle Fortschritte in der Dermatoonkologie: 10. Jahretagung der Arbeitsgemeinschaft für Dermatologische Onkologie (ADO). *Onkologie* 7: 92-102.
- 112) Menzel R, Durst C, Erber J, **Eichmüller S**, Hammer M, Hildebrandt H, Mauelshagen J, Müller U, Rosenboom H, Rybak J, Schäfer S, and Scheidler A (1994) The Mushroombodies in the Honeybee: From Molecules to Behavior; in *Neural Basis of*

Behavioral Adaptations. Fortschritte der Zoologie. Gustav Fischer Verlag: Stuttgart, p. 81-102.